The influence of coadministration of PPIs on pharmacodynamics of clopidogrel

The influence of coadministration of PPIs on pharmacodynamics of clopidogrel - The influence of coadministration of PPIs on pharmacodynamics of clopidogrel

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000003668

Enrollment

Registered

2010-06-01

Start date

2010-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ischemic heart disease

Interventions

After administration of ranitidine 300mg for 14 days, patients receive omeprazole 20mg for 14 days, and then receive ranitidine 300mg for 14 days again. Finally they receive rabeprazole 10mg for 14 da

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who are taking clopidogrel and aspirin, and have reflux esophagitis.

Exclusion criteria

Exclusion criteria: Drug allergy of study drugs; aspirin, clopidogrel, omeprazole, rabeprazole and ranitidine. Severe chronic renal failure Severe liver dysfunction

Design outcomes

Primary

Measure	Time frame
Platelet aggregation rate after intake of omeprazole or rabeprazole for 14 days	—

Countries

Japan

Contacts

Public ContactShigenobu Inami

Nippon Medical School Department of Internal Medicine Division of Cardiology, Hepatology, Geriatrics and Integrated Medicine

sigenobu@nms.ac.jp03-3822-2131

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026